Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/27/2012CA2531505C (20s)-1.alpha.-hydroxy-2-methylene-19-nor-vitamin d3 and its uses
11/27/2012CA2530706C 2-amino-bicyclo[3.1.0] hexane-2,6-dicarboxylic ester derivative
11/27/2012CA2526816C The use of oxicam compounds
11/27/2012CA2525214C Macrocyclic quinazoline derivatives as antiproliferative agents
11/27/2012CA2515790C Heterocyclic kinase inhibitors
11/27/2012CA2513310C Indenoncarboxylic acids derivatives and their use for the treatment of and preventing diabetes and dyslipidaemia
11/27/2012CA2488404C Genes and polypeptides relating to human colon cancers
11/27/2012CA2487805C Peptide deformylase inhibitors
11/27/2012CA2481390C Nanoparticulate megestrol formulations
11/27/2012CA2467374C Indole-2-carboxamides as factor xa inhibitors
11/27/2012CA2451051C Siglec inhibitors
11/27/2012CA2449830C New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents
11/27/2012CA2449157C Capping enzyme of flavivirus and utilization of this protein in a process to test drugs with antiviral properties
11/27/2012CA2414247C Cosmetic composition and method comprising a hydroxamate mmpi and a triterpenoid glycoside
11/27/2012CA2359360C In vitro screening method for identifying selective binding partners for 5-ht5-receptors
11/27/2012CA2333755C The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
11/27/2012CA2261231C Process using ulkenia sp. to prepare docosahexaenoic acid and docosapentaenoic acid
11/27/2012CA2181832C Immunization by inoculation of dna transcription unit
11/23/2012DE202010017863U1 Zusammensetzung zur Linderung von Gelenkschmerzen Composition for the relief of joint pain
11/22/2012WO2012159122A1 Heparin-based compositions and methods for the inhibition of metastasis
11/22/2012WO2012159107A1 Inhibition of renal fibrosis
11/22/2012WO2012159064A1 High concentration olopatadine ophthalmic composition
11/22/2012WO2012158994A1 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
11/22/2012WO2012158979A1 Quinazoline-7-ether compounds and methods of use
11/22/2012WO2012158957A2 Kinase modulation and indications therefor
11/22/2012WO2012158885A1 Deuterated derivatives of ivacaftor
11/22/2012WO2012158884A1 Pharmaceutical compositions and methods for treating cancer
11/22/2012WO2012158844A1 Heterocyclic compounds
11/22/2012WO2012158811A2 Purine monophosphate prodrugs for treatment of viral infections
11/22/2012WO2012158810A1 Tyrosine kinase inhibitors
11/22/2012WO2012158795A1 Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
11/22/2012WO2012158785A1 Azaindole derivatives as tyrosine kinase inhibitors
11/22/2012WO2012158784A2 Modulators of the nuclear hormone receptor ror
11/22/2012WO2012158764A1 Tyrosine kinase inhibitors
11/22/2012WO2012158699A1 Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
11/22/2012WO2012158672A2 Compounds for use in treatment of mucositis
11/22/2012WO2012158658A1 Fused bicyclic kinase inhibitors
11/22/2012WO2012158612A1 Method of treating postural reflex abnormality caused by parkinson's disease
11/22/2012WO2012158550A2 Selective heterocyclic sphingosine 1 phosphate receptor modulators
11/22/2012WO2012158517A1 The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
11/22/2012WO2012158475A1 N-linked lactam m1 receptor positive allosteric modulators
11/22/2012WO2012158474A1 N-linked quinolineamide m1 receptor positive allosteric modulators
11/22/2012WO2012158473A1 N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
11/22/2012WO2012158413A2 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
11/22/2012WO2012158405A2 Compositions and methods for the treatment of skin diseases
11/22/2012WO2012158399A1 Condensed 2 - carbamoylpyridazinones as potassium channel modulators
11/22/2012WO2012158362A1 Induction of immune tolerance by using methotrexate
11/22/2012WO2012158312A2 Skin and hair regeneration using polysaccharide-based hydrogels
11/22/2012WO2012158271A1 Bridged polycyclic compounds as antiviral agents
11/22/2012WO2012158123A1 Compounds and methods for treating insulin resistance syndrome
11/22/2012WO2012158117A1 Combination therapies for treating pain
11/22/2012WO2012158030A2 Drug delivery system
11/22/2012WO2012158003A1 Novel factor xii inhibitor
11/22/2012WO2012158002A1 Medicinal preparation "renessans" having an antibacterial, anti-ulcerous and immuno-modulating action
11/22/2012WO2012157817A1 Acne treatment composition using mal
11/22/2012WO2012157752A1 Pharmaceutical composition containing loxoprofen
11/22/2012WO2012157746A1 Therapeutic drug for autoimmune disease
11/22/2012WO2012157744A1 1-THIOXO-1,2,3,4-TETRAHYDRO-β-CARBOLINE DERIVATIVE AND ANTI-CANCER AGENT COMPRISING SAME
11/22/2012WO2012157737A1 Immunity inducing agent
11/22/2012WO2012157736A1 Immunity induction agent
11/22/2012WO2012157734A1 Wrinkle-improving composition containing placenta-derived component
11/22/2012WO2012157721A1 Liposome containing pyrroloquinoline quinone and sugar
11/22/2012WO2012157672A1 Method for predicting effectiveness of angiogenesis inhibitor
11/22/2012WO2012157647A1 Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
11/22/2012WO2012157612A1 Cell differentiation inducer and differentiation inducing method
11/22/2012WO2012157587A1 Anti-wrinkle agent, matrix metalloproteinase (mmp) inhibitor and/or laminin 5 production promoter, each comprising 1-piperidine propionate
11/22/2012WO2012157389A1 Low-molecular-weight compound capable of regulating rac activation induced by dock-a subfamily molecule, and use thereof
11/22/2012WO2012157290A1 Prophylactic/ameliorating agent for non-alcoholic steatohepatitis
11/22/2012WO2012157288A1 Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
11/22/2012WO2012157239A1 Chodl as tumor marker and therapeutic target for cancer
11/22/2012WO2012157128A1 Metal complex and pharmaceutical composition containing same
11/22/2012WO2012156999A1 Ready to use docetaxel formulation
11/22/2012WO2012156981A1 Pharmaceutical compositions of lurasidone
11/22/2012WO2012156979A1 A water soluble composition comprising curcumin having enhanced bioavailability and process thereof
11/22/2012WO2012156951A1 Polymorph of rifaximin and process for the preparation thereof
11/22/2012WO2012156936A1 Substituted indole derivatives for the treatment of immunological disorders
11/22/2012WO2012156931A1 Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof
11/22/2012WO2012156917A2 Method for obtaining epsilon-viniferin and/or resveratrol and corresponding products
11/22/2012WO2012156913A1 An antioxidant composition
11/22/2012WO2012156877A1 Epicutaneous. skin cancer, basal, squamous, melanoma, collagen, procolla1, mmp1
11/22/2012WO2012156822A1 Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
11/22/2012WO2012156821A1 Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
11/22/2012WO2012156820A1 Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
11/22/2012WO2012156756A2 New compounds
11/22/2012WO2012156677A1 A stable micronised monoclinic form of asenapine maleate and its synthesis
11/22/2012WO2012156676A1 Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
11/22/2012WO2012156600A1 Bixa orellana composition for treating macular degeneration
11/22/2012WO2012156599A1 The use of secnidazole in treating dental infections
11/22/2012WO2012156565A1 Injectable preparation of melatonin
11/22/2012WO2012156561A1 Controlled-release injectable microparticle
11/22/2012WO2012156537A2 Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
11/22/2012WO2012156533A1 New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
11/22/2012WO2012156531A2 Lysine demethylase inhibitors for inflammatory diseases or conditions
11/22/2012WO2012156527A1 Pharmaceutical composition having improved bioavailability
11/22/2012WO2012156498A1 Quinazoline derivatives for the treatment of viral infections and further diseases
11/22/2012WO2012156497A1 Use of sigma ligands in diabetes type-2 associated pain
11/22/2012WO2012156467A1 Novel pkc inhibitors
11/22/2012WO2012156463A1 Novel cancer therapies and methods
11/22/2012WO2012156384A1 Novel crystalline salts of asenapine
11/22/2012WO2012156383A1 Novel crystalline salts of asenapine with organic di-acids and tri-acids
1 ... 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 ... 7860